## **COVID-19: Clinical Presentation & Management**

Pathogen: SARS-CoV-2

Disease: Coronavirus disease 2019 (COVID-19)

#### **Basic Biology:**

- (+) ssRNA, large, enveloped beta-coronavirus
- Zoonotic origin with mammalian sources including the bat, pangolin, or snake
- SARS-CoV-2 spike (S) protein binds the ACE2 receptor and requires TMPRSS2 and furin proteases to facilitate host cell entry

# Transmission: viral particle entry via <u>respiratory droplets</u>

### Pathogenesis:

- Infection of type II pneumocytes in the lung by SARS-CoV-2 particles
- 2. Impaired interferon response and cytolysis results in increased levels of inflammatory cytokines and chemokines in the circulation (IL-6, IL-8, TNF)
- 3. Vasodilation and increased vascular permeability
- 4. Edema and compression of alveoli
- Decreased production of lung surfactant, reduced gas exchange → ARDS

#### Epidemiology:

- $R_0$  (no. of infections from 1 case) = 2.5-2.9
- Attack rate = 0.25%
- CFR = 1.3% (influenza CFR = 0.1%)
- Incubation time = 5.2 days (-14 days)
  - Affected populations: > <u>Pediatric patients</u> (multisystem inflammatory syndrome in children [**MIS-C**]): Kawasaki-like syndrome with fever, hypotension, GI symptoms, rash, *myocarditis*; respiratory symptoms may be absent
    - > Pregnant women: complications of the maternal/placental vasculature (e.g., microthrombi formation), preeclampsia
    - > Elderly patients: mortality in pts > 75 is 75x rate among 18-44-year-olds

#### Control Strategies (WHO):

- Social distancing / quarantine
- Use of face masks
- Contact tracing and screening

#### **Recommended Precautions:**

- Hand hygiene: soap/water for 20 sec when visibly soiled, before eating, and after restroom use; otherwise, alcohol-based hand rub and gloves
- Airborne precautions for aerosolizing procedures (intubation, suction, NIPPV)
- Droplet precautions (all else)

Therapeutic Options Available for COVID-19				
FDA-approve	ed	In clinical trial		Compassionate use
Class	Drug	Mechanism of Action		
Antivirals	Remdesivir	(broad-spectrum): nucleotide analog		
	Lopinavir	(broad-spectrum): protease inhibitor		
	Ritonavir	(broad-spectrum): protease inhibitor		
Immuno-modulators	HCQ	No longer a treatment for COVID-19		
	Tocilizumab	(monoclonal Ab) inhibits IL-6 receptor		
	Sarilumab	(monoclonal Ab) inhibits IL-6 receptor		
	Siltuximab	(monoclonal Ab) inhibits IL-6		
	Gimsilumab	(monoclonal Ab) inhibits GM-CSF		
	Eculizumab	inihibiton of C5a complement protein		
	Cenicriviroc	inhibition of CCR2 and CCR5		
	IFN-λ	exogenous interferon therapy		
	Remestemcel-L	mesenchymal stem cell transfer		
	Convalescent Plasma	(hyperimmune globulin)		

Park MD and Schussler L. June 2020.

Symptoms: Cough (76%), fever (98%), dyspnea (50%), myalgias or fatigue (44%), GI (10%)


- Asymptomatic (1.2%)
- Mild to medium (80.9%)
- Severe (13.8%)
- Critical (4.7%) -- death (2.3%)

#### Laboratory Assessment:

- ↑ CRP, ferritin, D-dimer, PCT, LDH
- ↑ IL-6, IL-10, TNF-α
- Liver function tests (LFTs)
- ↑ AST/ALT
- ↑ Total bilirubin
- Basic metabolic panel (BMP)
- ↑ BUN / Cr
  - Complete blood count (CBC)
  - ↓ lympho-/leukocytes

#### Imaging:

- CXR/CT
- Bilateral, multilobar involvement
- GGO and consolidation (below)



- POCUS (Point-of-care ultrasound)
- B-lines, pleural lines, air bronchograms

#### Prognosis:

- Risk factors
- Age; cardiovascular, endocrine, liver and pulmonary disease; CKD, obesity, cancer, residence in nursing homes/long-term care facilities

#### Independent Predictors of Clinical Severity

- ↑ CRP, LDH, lymphocyte count, IL-6, TNF-α, Ddimer

#### Complications

- ARDS
- Sepsis
- AKI
- Transaminitis
- Venous thromboembolic events
- Cardiac (cardiomyopathy, HF, MI, arrhythmias)
- Empyema

#### COVID calculators: <a href="https://www.mdcalc.com/covid-19">https://www.mdcalc.com/covid-19</a>

#### Management Strategy:

Testing

RT-PCR (order early - can take days; see testing criteria)
66-80% sensitive; i.e. 20-34% false negative rate

#### Basic care

- Lung protective ventilation, proning, restrictive fluid management and management of organ failures
- SpO<sub>2</sub> target ≥ 93%
- Oxygenation HFNC, face mask, or noninvasive ventilation
- Systemic anticoagulation (see pathway)

#### Mechanical ventilation

- Indicated by SaO<sub>2</sub> < 93-96% + acute lung injury</li>
- 7 P's: PEEP, Paralysis, Prone positioning, Prostacyclins, Pleural evacuation, Peeing (diuresis), Peripheral oxygenation (ECMO)

#### Drugs / vaccines

 Remdesivir is the only FDA-approved drug (nucleotide analog, inhibits RNA-dependent RNA polymerase)